Hong Kong possesses a distinct advantage in biotechnology development, recognized as one of the world’s leading fundraising hubs for biotech companies. With robust research and development capabilities, HK is home to five universities ranked among the top 100 globally, while InnoHK serves as a pivotal hub for R&D in life and health technologies. 16 companies from Hong Kong Science and Technoloy Parks Corporation (HKSTP) participate BIO25 in HK Pavilion. | Hong Kong Science & Technology Parks Corporation (HKSTP) is a leading innovation and technology hub established in 2002. It fosters a vibrant ecosystem for startups, enterprises, and researchers, offering incubation, acceleration, and investment opportunities. HKSTP operates Science Park, InnoCentre, and InnoParks across Hong Kong, driving advancements in life sciences, AI, fintech, and more. With strong global partnerships, state-of-the-art facilities, and talent development programs, HKSTP accelerates innovation and commercialization, contributing to Hong Kong’s position as a regional I&T leader.
CNCure Co., Ltd.
CNCure is a pioneering biotech startup dedicated to revolutionizing cancer therapy and diagnostics. We specialize in developing bacteria-based cancer immunotherapeutics and theranostic platforms leveraging microbial theapeutics and nuclear medicine. One of our core technologies is the Salmonella-based Armed Microbe (SAM) platform, which utilizes innovative approaches to target tumors and enhance anticancer immune responses. Our flagship products, CNC-101 and CNC-105, directly target tumors, induce immune responses, and establish long-term antitumor immunological memory to prevent recurrence. In addition, CNCure is advancing diagnostic technologies with radiotracer-based tools for the high-sensitivity detection of fatal diseases such as fungal infections. Our [18F]FDS and [18F]DMPY2 tracers enable high-resolution visualization of gram-negative bacterial and fungal infections and malignant melanoma, respectively. CNCure is dedicated to pioneering innovations in cancer treatment, striving to improve patient outcomes and quality of life on a global scale. By actively participating in numerous national and international R&D projects, we continue to drive groundbreaking research and development. Our extensive patent portfolio is a testament to our technological excellence and commitment to shaping the future of oncology. Founded in 2019 by leading experts in cancer immunotherapy and radiopharmaceuticals, CNCure has developed a robust scientific foundation, a cutting-edge technology platform, and a strong pipeline. In the second half of 2024, we were honored to be one of only 14 companies, out of over 100 applicants, selected for Johnson & Johnson’s JLABS Korea program, which aims to accelerate life-science innovation. As we advance the clinical development and commercialization of our theranostic candidates, we actively seek joint-development partnerships and investments to expand our global presence. Our vision is to revolutionize cancer treatment through groundbreaking bacteria-based immunotherapies and radiopharmaceuticals that address critical unmet medical needs. | CNCure Co., Ltd. is a pioneering biotechnology company based in Hwasun, Republic of Korea, dedicated to revolutionizing cancer therapy and diagnostics. Founded in 2019, CNCure specializes in bacteria‑based cancer immunotherapeutics and integrated theranostic platforms leveraging microbial and nuclear medicine. The company’s lead candidate, CNC‑101, is a next‑generation bacterial immunotherapy built on attenuated Salmonella typhimurium technology, designed to selectively colonize the tumor microenvironment and reprogram it into an immuno‑active state that enhances anti‑tumor immune responses. Preclinical data demonstrate promising efficacy and safety profiles across multiple solid tumor models. Beyond immuno‑oncology, CNCure is advancing radiopharmaceutical and theranostic platforms that combine imaging and therapy for improved tumor targeting, treatment monitoring, and personalized decision‑making. CNCure actively pursues global partnerships and business development to translate its innovative platforms into clinical applications that address unmet medical needs. CNCure continues to present its scientific and clinical progress at major international conferences.
BIOTECHNOLOGY VALLEY
The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.